Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Transitional Cell 3Urinary Bladder Neoplasms 2Urologic Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms 1Carcinoma in Situ 1

Interventions

apaziquone 4Mitomycin 3viscum album peptide 1valrubicin 1pembrolizumab 1linrodostat 1enzalutamide 1enfortumab vedotin 1avelumab 1Sugars 1Standard of Care 1Polysorbates 1Pentosan Sulfuric Polyester 1Nivolumab 1Gemcitabine 1DDMS 1Capsules 1Bevacizumab 1ALT-801 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Non-Muscle Invasive Bladder Neoplasms × enfortumab vedotin × Clear all
NCT05014139 2025-11-20

A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)

Astellas Pharma Inc

Phase 1 Terminated
37 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡